Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

SELL
$14.09 - $19.87 $13,667 - $19,273
-970 Reduced 1.08%
88,490 $1.4 Million
Q2 2023

Aug 15, 2023

BUY
$3.75 - $20.05 $335,475 - $1.79 Million
89,460 New
89,460 $1.69 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Castleark Management LLC Portfolio

Follow Castleark Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castleark Management LLC with notifications on news.